Spotlight on Quetiapine in Bipolar Depression

Authors: Keating, Gillian M.; Robinson, Dean M.

Source: CNS Drugs, Volume 21, Number 8, 2007 , pp. 695-697(3)

Buy & download fulltext article:

Price: $57.95 plus tax (Refund Policy)

Abstract:

Quetiapine (Seroquel^®) is the only atypical antipsychotic approved in the US for use as monotherapy in both bipolar mania and depression, offering potential compliance advantages. Monotherapy with oral quetiapine 300 mg/day is effective in the treatment of patients with bipolar I or II depression. Rapid and sustained improvements in depressive and anxiety symptoms are seen with quetiapine, as well as improvements in health-related quality of life. Quetiapine is generally well tolerated in bipolar depression and is not associated with an increased risk of treatment-emergent mania. Thus, despite the current lack of data from active comparator trials, quetiapine monotherapy should be considered a first-line option for the acute treatment of bipolar depression.

Keywords: Adis Spotlights; Antipsychotics; Bipolar depression; Bipolar disorders; Quetiapine

Document Type: Research article

Affiliations: 1: Wolters Kluwer Health | Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA

Publication date: 2007-01-01